NRP1 and breast carcinoma: Barr and co-workers demonstrated in 2005 [11] that a peptide targeting the VEGF165-binding site of NRP1, antagonises the autocrine anti-apoptotic effects of VEGF in cultured 4T1 and MDA-MB-231 breast carcinoma cells.